课题基金 / 基金详情

项目摘要

项目成果

Andrew S Kraft的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Hollings Cancer Center (HCC) Cell Evaluation & Therapy (CET) Shared Resource offers HCC investigators comprehensive analytic flow cytometry and high-speed cell sorting services and the capacity to generate human cellular and tissue-based products for use in translational research. The mission of the CET Shared Resource is to provide an integrated platform where HCC users can evaluate pre-clinical or clinical experimental data in a cell-specific manner and use the cell-manufacturing facility to bring the cellular product to patients. Directed by Kevin F. Staveley-O'Carroll, MD, PhD, with two Associate Directors, Amanda C. LaRue, PhD and Shikhar Mehrotra, PhD, this facility provides extensive expertise, an active educational platform, and development of new methodologies within the facility. The specific objectives of the HCC CET Shared Resource are to provide: • Multi-parametric and multi-laser measurements including apoptosis, cell proliferation, cell cycle distribution, and immunophenotyping, as well as detection of intracellular proteins, membrane perturbations, and bioactive molecules. • Expanded cell therapy and gene therapy-based bio-therapeutic products for Phase I and II clinical studies employing current cGMP as required by federal regulations. • Immune monitoring services to evaluate the immune response in patients and provide data for basic laboratory experiments. • Regulatory expertise in the preparation of cell and possibly gene therapy based INDs. • High-speed cell sorting based on cell surface marker immunostaining and/or side-population staining. • Consultation and assistance concerning experimental design, sample preparation, and data analysis. • Training in the use of routine flow cytometric technology and analytical equipment. • Advanced training in novel flow cytometric assays that are new and/or specific to HCC researchers' applications. • New methods to assist HCC members in performing cutting-edge research. CET-supported experiments during the current CCSG project period have led to the success of more than 18 NCI-funded research project grants and more than 100 peer-reviewed publications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of RNA Decapping and Degradation: A novel approach to prostate cancer therapy
  • 批准号:
    10758110
  • 项目类别:
  • 资助金额:
    $39.72万
  • 财政年份:
    2023
  • 负责人:
    Andrew S Kraft
  • 依托单位:
Pim 1 Protein Kinase in Regulating Stromal Cell Biology in Prostate Cancer
  • 批准号:
    8855025
  • 项目类别:
  • 资助金额:
    $19.96万
  • 财政年份:
    2015
  • 负责人:
    Andrew S Kraft
  • 依托单位:
MUSC/HCC Paul Calabresi Clinical Oncology Training Program Plan
Targeting the Pim 1 Protein Kinase to Overcome Resistance to AKT Inhibitors
海外基金